Ron Peck, MD, CMO of Arvinas @Arvinas discusses an orally-active proteolysis targeting chimera (PROTAC) molecule being developed to treat men with metastatic prostate cancer, and ARV-471, a potential treatment for patients with locally advanced or metastatic breast cancer. Dr. Peck further explains the approach to targeted protein degradation and why it might have potential in oncology.
The results of both trials showed a favorable overall safety profile, and exposures reaching levels predicted by preclinical studies to be efficacious.
The company will report initial efficacy data this year, which will be a huge step in proving the concept of PROTAC protein degraders as drugs.
Degradation of proteins has a major therapeutic promise: PROTAC protein degraders can remove almost all of a target protein, including mechanisms of oncology resistance where disease-causing proteins are over-produced. Across a wide range of clinical fields, from oncology and neurodegenerative diseases to cardiovascular and gynecological diseases, targeted protein degradation may be used.